Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : 1000% returns are cool !!! -- Ignore unavailable to you. Want to Upgrade?

To: Sam Nizam who wrote (636)	6/7/2000 6:58:00 PM
From: Tarzan	Respond to of 3326

Looking for insights on Celsion Corporation (CLN) Paul Harvey was talking about this today. Comments appreciated! Monday June 5, 10:25 am Eastern Time Company Press Release Massachusetts Institute of Technology Issues Press Release On Its Breast Cancer Treatment Technology, Exclusively Licensed to Celsion Corporation COLUMBIA, Md.--(BUSINESS WIRE)--June 5, 2000--Celsion Corporation (AMEX:CLN - news) announced today that Massachusetts Institute of Technology (MIT), located in Cambridge, MA, has issued a press release detailing the history and development of its breast cancer treatment technology, which is licensed exclusively to Celsion Corporation. The full release can be viewed at the MIT News Office web page, at web.mit.edu. The technology upon which the breast cancer treatment is based was initially developed ten years ago by Dr. Alan J. Fenn, senior staff member of the Advanced Electromagnetic Systems Group at Lincoln Laboratory, MIT. The technique utilizes microwave signals to heat and kill cancer cells in breast tissue. Its efficacy is based on the fact that cancer cells contain almost 80% water, while healthy cells contain less than 20% water. The microwave signal targets the heat at the cancerous cells, ablating (killing) them through superheating, while avoiding overheating the healthy tissue. Side effects appear to be limited to slight fever following the procedure. As of this spring, seven women have participated in an FDA-approved clinical study of the treatment; three other women will soon be treated. The next trial, (Phase II Clinicals), which could be completed within the year, will include 100 patients who will be treated for early-stage or advanced breast cancer. MIT has exclusively licensed the technology to Celsion Corporation, which underwrites the clinical trials required by the FDA. Spencer Volk, Celsion President and Chief Executive Officer of Celsion, stated, ``Celsion is proud to be the sponsor of such a critically important treatment technique in the fight against breast cancer. We will continue to fully support the clinical trial process until we can bring the treatment - with complete FDA approval - to the medical community and breast cancer patients at large.'' About Celsion: Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused heat technology delivered by patented microwave technology. Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, the University of California at San Francisco, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center in New York and Duke University.